Page last updated: 2024-11-05

trazodone and Barre-Lieou Syndrome

trazodone has been researched along with Barre-Lieou Syndrome in 1 studies

Trazodone: A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309)
trazodone : An N-arylpiperazine in which one nitrogen is substituted by a 3-chlorophenyl group, while the other is substituted by a 3-(3-oxo[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)propyl group.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Morinaga, Y1
Nii, K1
Hanada, H1
Takemura, Y1
Sakamoto, K1
Inoue, R1
Mitsutake, T1
Tsugawa, J1
Kurihara, K1
Tateishi, Y1
Higashi, T1

Other Studies

1 other study available for trazodone and Barre-Lieou Syndrome

ArticleYear
Clinical features of Barré-Lièou syndrome and efficacy of trazodone for its treatment: A retrospective single center study.
    Drug discoveries & therapeutics, 2021, May-11, Volume: 15, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Autonomic Nervous System;

2021